Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute treatments: future developments.

N M Ramadan1

  • 1Lilly Research Laboratories, Eli Lilly & Co. and Indiana University School of Medicine, Indianapolis, Indiana 46285, USA. ramadan@lilly.com

Current Medical Research and Opinion
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of intrauterine growth pattern on serum visfatin concentrations in full-term infants at birth and at 6 months of life.

Journal of neonatal-perinatal medicine·2016
Same author

Factors determining headache at onset of acute ischemic stroke.

Cephalalgia : an international journal of headache·2006
Same author

Meningeal enhancement and low CSF pressure headache. An MRI study.

Cephalalgia : an international journal of headache·2005
Same author

LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

Cephalalgia : an international journal of headache·2004
Same author

5-HT1F receptor agonists in acute migraine treatment: a hypothesis.

Cephalalgia : an international journal of headache·2003
Same author

Emerging trends in the pharmacotherapy of chronic pain.

Expert opinion on investigational drugs·2003
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
Same journal

Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

Current medical research and opinion·2026
See all related articles

Future migraine therapies focus on CGRP antagonists, nitric oxide synthase inhibitors, and glutamate receptor antagonists. These novel treatments aim for high efficacy with improved safety and tolerability, with trials underway.

Area of Science:

  • Neurology
  • Pharmacology
  • Drug Development

Background:

  • Previous anti-migraine drug development faced challenges and dead ends.
  • Current acute treatments may have limitations in efficacy or tolerability.
  • Emerging research targets novel pathways for migraine management.

Purpose of the Study:

  • To review promising future therapeutic targets for acute migraine.
  • To discuss the potential of novel drug classes in migraine treatment.
  • To highlight the ongoing research and development in anti-migraine therapies.

Main Methods:

  • Review of current literature and clinical trial data.
  • Discussion of emerging drug targets including CGRP antagonists, NOS inhibitors, and glutamate receptor antagonists.

Related Experiment Videos

  • Analysis of the potential efficacy and safety profiles of novel agents.

    • Main Results:

    • Growing interest and support for CGRP antagonists, nitric oxide synthase inhibitors, and ionotropic glutamate receptor antagonists.
    • Several novel targets are in early efficacy or first human dose trials.
    • Anticipation for large-scale efficacy and safety trials of these future therapies.

    Conclusions:

    • Novel drug targets show promise for effective and well-tolerated migraine treatment.
    • The development pipeline for acute migraine therapies is advancing with promising candidates.
    • Further clinical trials are crucial to validate the efficacy and safety of these future migraine treatments.